DK1925297T4 - Fremgangsmåde til fremstilling af mikropartikler med en udvalgt polymermole-kylvægt - Google Patents

Fremgangsmåde til fremstilling af mikropartikler med en udvalgt polymermole-kylvægt

Info

Publication number
DK1925297T4
DK1925297T4 DK08102276.6T DK08102276T DK1925297T4 DK 1925297 T4 DK1925297 T4 DK 1925297T4 DK 08102276 T DK08102276 T DK 08102276T DK 1925297 T4 DK1925297 T4 DK 1925297T4
Authority
DK
Denmark
Prior art keywords
molecular weight
selected polymer
microparticles
preparation
polymer molecular
Prior art date
Application number
DK08102276.6T
Other languages
English (en)
Other versions
DK1925297T3 (da
Inventor
Steven G Wright
Michael E Rickey
Shawn L Lyons
Joyce M Hotz
Michael J Ramstack
Original Assignee
Alkermes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24298824&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1925297(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alkermes Inc filed Critical Alkermes Inc
Publication of DK1925297T3 publication Critical patent/DK1925297T3/da
Application granted granted Critical
Publication of DK1925297T4 publication Critical patent/DK1925297T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Polyamides (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polyesters Or Polycarbonates (AREA)
DK08102276.6T 2000-05-19 2001-04-19 Fremgangsmåde til fremstilling af mikropartikler med en udvalgt polymermole-kylvægt DK1925297T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/575,075 US6264987B1 (en) 2000-05-19 2000-05-19 Method for preparing microparticles having a selected polymer molecular weight
EP01928630A EP1282404B1 (en) 2000-05-19 2001-04-19 Method for preparing microparticles having a selected polymer molecular weight

Publications (2)

Publication Number Publication Date
DK1925297T3 DK1925297T3 (da) 2012-10-08
DK1925297T4 true DK1925297T4 (da) 2017-11-06

Family

ID=24298824

Family Applications (2)

Application Number Title Priority Date Filing Date
DK01928630T DK1282404T3 (da) 2000-05-19 2001-04-19 Fremgangsmåde til fremstilling af mikropartikler med en selekteret polymermolekylvægt
DK08102276.6T DK1925297T4 (da) 2000-05-19 2001-04-19 Fremgangsmåde til fremstilling af mikropartikler med en udvalgt polymermole-kylvægt

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK01928630T DK1282404T3 (da) 2000-05-19 2001-04-19 Fremgangsmåde til fremstilling af mikropartikler med en selekteret polymermolekylvægt

Country Status (12)

Country Link
US (6) US6264987B1 (da)
EP (3) EP1925297B2 (da)
JP (1) JP4903344B2 (da)
AT (1) ATE399535T1 (da)
AU (2) AU5546501A (da)
CA (1) CA2405787C (da)
CY (2) CY1110403T1 (da)
DE (1) DE60134640D1 (da)
DK (2) DK1282404T3 (da)
ES (2) ES2391315T5 (da)
PT (2) PT1282404E (da)
WO (1) WO2001089482A2 (da)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194006B1 (en) * 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US6264987B1 (en) * 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US7666445B2 (en) 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
ES2382636T3 (es) * 2000-10-31 2012-06-12 Surmodics Pharmaceuticals, Inc. Método para producir composiciones para la administración mejorada de moléculas bioactivas
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
AU2002366710A1 (en) * 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US20030176929A1 (en) * 2002-01-28 2003-09-18 Steve Gardner User interface for a bioinformatics system
ES2334991T3 (es) * 2002-03-26 2010-03-18 Teva Pharmaceutical Industries Ltd. Microparticulas de farmaco.
US20040142887A1 (en) * 2002-07-10 2004-07-22 Chengji Cui Antigen-polymer compositions
DE10235556A1 (de) * 2002-08-03 2004-02-19 Hf Arzneimittelforschung Gmbh Medikament und Verfahren zur Verringerung des Alkohol- und/oder Tabakkonsums
WO2004034888A2 (en) * 2002-10-18 2004-04-29 Ellis Charles N Method for rating severity of psoriasis
WO2004064752A2 (en) * 2003-01-22 2004-08-05 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
US20070207211A1 (en) * 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
CA2516107C (en) * 2003-04-10 2013-12-24 Ehud Zeigerson A method for production of emulsion-based microparticles
EP1628664A4 (en) * 2003-06-04 2008-11-05 Alkermes Inc POLYMORPHIC FORMS OF NALTREXONE
JP5165239B2 (ja) * 2003-07-15 2013-03-21 ピーアール ファーマシューティカルズ， インコーポレイテッド 制御放出処方物の調製のための方法
DK1660039T3 (da) 2003-07-18 2017-01-16 Oakwood Laboratories L L C Forebyggelse af reduktion af polymerens molekylvægt, dannelse af urenheder og gelering i polymersammensætninger
WO2005009357A2 (en) * 2003-07-23 2005-02-03 Pr Pharmaceuticals, Inc. Controlled release compositions
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
EP1663289A2 (en) * 2003-08-29 2006-06-07 Amylin Pharmaceuticals, Inc. Methods for treating or ameliorating ghrelin-associated diseases and disorders
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US8329203B2 (en) 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
EP1711124A4 (en) * 2004-01-12 2011-06-01 Univ Pennsylvania LONG-TERM RELEASE PREPARATIONS AND METHODS OF USE THEREOF
WO2006083254A1 (en) * 2004-02-11 2006-08-10 Amylin Pharmaceuticals, Inc. Amylin family peptides and methods for making and using them
JP5179757B2 (ja) * 2004-02-17 2013-04-10 トランセプト ファーマシューティカルズ， インコーポレイティド 口腔粘膜を介して催眠剤をデリバリーするための組成物及びその使用方法
US7399744B2 (en) * 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
US20050245461A1 (en) * 2004-03-19 2005-11-03 Elliot Ehrich Methods for treating alcoholism
US20050245541A1 (en) * 2004-03-19 2005-11-03 Elliot Ehrich Methods for treating alcoholism
US7919499B2 (en) * 2004-04-22 2011-04-05 Alkermes, Inc. Naltrexone long acting formulations and methods of use
US20050260272A1 (en) * 2004-05-05 2005-11-24 Alkermes Controlled Therapeutics, Inc. Method of forming microparticles that include a bisphosphonate and a polymer
WO2006052608A2 (en) 2004-11-01 2006-05-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
JP5743371B2 (ja) 2004-12-13 2015-07-01 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 膵臓ポリペプチドファミリーモチーフ、ポリペプチドおよびこれらを含む方法
WO2006078841A1 (en) * 2005-01-21 2006-07-27 President And Fellows Of Harvard College Systems and methods for forming fluidic droplets encapsulated in particles such as colloidal particles
AU2006213607A1 (en) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Llc GIP analog and hybrid polypeptides with selectable properties
EA013121B1 (ru) 2005-03-31 2010-02-26 Амилин Фармасьютикалз, Инк. Амилин и агонисты амилина для лечения психиатрических заболеваний и расстройств
US20070287740A1 (en) * 2005-05-25 2007-12-13 Transcept Pharmaceuticals, Inc. Compositions and methods of treating middle-of-the night insomnia
US20070225322A1 (en) * 2005-05-25 2007-09-27 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the night insomnia
US8242131B2 (en) * 2005-05-25 2012-08-14 Transcept Pharmaceuticals, Inc. Methods of treating middle-of-the-night insomnia
CA2614601C (en) * 2005-07-18 2015-04-07 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
CA2621167A1 (en) * 2005-08-30 2007-03-08 Acologix, Inc. Regulation of mineral and skeletal metabolism
US20070081972A1 (en) * 2005-09-30 2007-04-12 The University Of Iowa Research Foundation Polymer-based delivery system for immunotherapy of cancer
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
WO2007130134A2 (en) * 2005-12-02 2007-11-15 (Osi) Eyetech, Inc. Controlled release microparticles
WO2008097536A2 (en) 2007-02-05 2008-08-14 Amylin Pharmaceuticals, Inc. Compositions and methods for treating psychiatric diseases and disorders
CA2687979C (en) 2007-05-25 2017-07-04 Tolmar Therapeutics, Inc. Sustained delivery formulations of risperidone compounds
WO2010030763A2 (en) * 2008-09-10 2010-03-18 Bind Biosciences, Inc. High throughput fabrication of nanoparticles
EP2389160B1 (en) * 2009-01-23 2017-09-13 Evonik Corporation Continuous double emulsion process for making microparticles
US20100196436A1 (en) * 2009-01-30 2010-08-05 Gooberman Lance L Implants containing disulfiram and an anti-inflammatory agent
US8791093B2 (en) * 2009-05-29 2014-07-29 Lance L. Gooberman Pharmaceutical delivery systems for treatment of substance abuse and other addictions
US20130165459A1 (en) 2010-01-12 2013-06-27 Norvartis Pharma Ag Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
EA201390450A1 (ru) 2010-09-28 2013-07-30 Амилин Фармасьютикалс, Ллк. Полипептиды с увеличенной продолжительностью действия
WO2012050925A2 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Inc. Highly soluble leptins
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
WO2012072824A1 (en) 2010-12-03 2012-06-07 Novartis Ag Pharmaceutical compositions, dosage forms and new forms of the compound of formula (i), and methods of use thereof
US9382304B2 (en) 2011-07-08 2016-07-05 Amylin Pharmaceuticals, Llc Engineered polypeptides having enhanced duration of action with reduced immunogenicity
PT2729160T (pt) 2011-07-08 2019-07-08 Aegerion Pharmaceuticals Inc Polipéptidos modificados com uma maior duração da ação e uma imunogenicidade reduzida
BRPI1106938A2 (pt) * 2011-10-17 2015-12-08 Fbm Indústria Farmacêutica Ltda composição farmacêutica de liberação controlada contendo naltrexona e topiramato
RU2471478C1 (ru) * 2011-12-08 2013-01-10 Станислав Анатольевич Кедик Фармацевтическая композиция для лечения алкоголизма, наркомании и токсикомании с улучшенным профилем высвобождения налтрексона
RS56427B2 (sr) 2013-06-20 2023-04-28 Pharmathen Sa Priprema polilaktidnih-poliglikolidnih mikročestica koje imaju sigmoidalni profil oslobađanja
WO2014202214A1 (en) 2013-06-20 2014-12-24 Pharmathen S.A. Preparation of polylactide-polyglycolide microparticles having a sigmoidal release profile
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
NZ731309A (en) 2014-11-07 2022-02-25 Indivior Uk Ltd Buprenorphine dosing regimens
EP3303585A4 (en) 2015-06-03 2018-10-31 Board of Regents of the University of Nebraska Dna editing using single-stranded dna
US20190029969A1 (en) * 2015-09-07 2019-01-31 Nipro Corporation Risperidone-containing microcapsule, method for preparing same and release control method
KR20230137362A (ko) 2016-05-05 2023-10-04 어퀘스티브 테라퓨틱스, 아이엔씨. 강화된 전달 에프네프린 조성물
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
WO2018031771A1 (en) 2016-08-11 2018-02-15 University Of Iowa Research Foundation CATIONIC CaMKII INHIBITING NANOPARTICLES FOR THE TREATMENT OF ALLERGIC ASTHMA
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
CN109718212A (zh) * 2017-10-30 2019-05-07 浙江圣兆药物科技股份有限公司 一种减少利培酮微球中低挥发溶剂苯甲醇的方法
TWI827777B (zh) * 2018-12-27 2024-01-01 昱展新藥生技股份有限公司 納曲酮注射型緩釋製劑
KR102072968B1 (ko) * 2019-05-28 2020-02-04 주식회사 울트라브이 생분해성 고분자 미세 입자의 제조 방법 및 조직 수복용 생분해성 재료
US20230313223A1 (en) 2019-10-15 2023-10-05 Cornell University Methods for modulating level of expression from gene therapy expression cassette
CA3157864A1 (en) 2019-10-16 2021-04-22 Cornell University Gene therapy for alzheimer's disease
US20230001017A1 (en) 2019-10-28 2023-01-05 University Of Lowa Research Foundation Formulation for delivery of lubricin gene
WO2021108809A1 (en) 2019-11-25 2021-06-03 Cornell University Apoe gene therapy
CN113546060B (zh) * 2020-04-08 2023-04-07 江苏长泰药业有限公司 一种纳曲酮微球
CA3176547A1 (en) 2020-04-23 2021-10-28 Milad ROUHIMOGHADAM Gper proteolytic targeting chimeras
US20230293678A1 (en) 2020-08-21 2023-09-21 Aliasger K. Salem Cationic nanoparticle adjuvants
US20230414787A1 (en) 2020-08-27 2023-12-28 University Of Iowa Research Foundation Gene knock-out for treatment of glaucoma
CN112245434A (zh) * 2020-11-09 2021-01-22 深圳善康医疗健康产业有限公司 一种纳曲酮和利培酮复方缓释组合物
US20240100183A1 (en) 2020-12-11 2024-03-28 University Of Iowa Research Foundation Compositions comprising molecules for cystic fibrosis treatment
WO2022246280A1 (en) 2021-05-21 2022-11-24 University Of Iowa Research Foundation Anti-oxidant containing particles and methods of use
WO2022271951A1 (en) 2021-06-23 2022-12-29 University Of Iowa Research Foundation Sustained release formulations comprising a selective androgen receptor modulator

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL280825A (da) 1962-07-11
BE744162A (fr) 1969-01-16 1970-06-15 Fuji Photo Film Co Ltd Procede d'encapsulage
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE2010115A1 (de) 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrogranulaten
JPS523342B2 (da) 1972-01-26 1977-01-27
GB1413186A (en) 1973-06-27 1975-11-12 Toyo Jozo Kk Process for encapsulation of medicaments
JPS523653A (en) 1975-06-27 1977-01-12 Fuji Photo Film Co Ltd Process for producing fine polymer particles
US4384975A (en) 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE59361B1 (en) 1986-01-24 1994-02-09 Akzo Nv Pharmaceutical preparation for obtaining a highly viscous hydrogel or suspension
AU2810189A (en) 1987-10-30 1989-05-23 Stolle Research & Development Corporation Low residual solvent microspheres and microencapsulation process
US5158952A (en) 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
IL92344A0 (en) 1989-01-04 1990-07-26 Gist Brocades Nv Microencapsulation of bioactive substances in biocompatible polymers,microcapsules obtained and pharmaceutical preparation comprising said microcapsules
AU5741590A (en) 1989-05-04 1990-11-29 Southern Research Institute Improved encapsulation process and products therefrom
US5478564A (en) 1990-02-22 1995-12-26 Teva Pharmaceutical Industries, Ltd. Preparation of microparticles for controlled release of water-soluble substances
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
HU222501B1 (hu) 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
US5658593A (en) 1992-01-16 1997-08-19 Coletica Injectable compositions containing collagen microcapsules
ATE193037T1 (de) 1992-02-28 2000-06-15 Collagen Corp Hochkonzentrierte homogenisierte kollagenzusammensetzungen
CA2129514A1 (en) * 1992-03-12 1993-09-16 M. Amin Khan Controlled released acth containing microspheres
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
FR2692147B1 (fr) * 1992-06-15 1995-02-24 Centre Nat Rech Scient Microsphères en polymère biorésorbable exemptes de tensioactif, leur préparation et leur application comme médicament.
CA2148823C (en) 1992-11-17 1999-03-09 Welfide Corporation Sustained release microsphere preparation containing antipsychotic drug and production process thereof
EP1013270A3 (en) 1992-12-02 2001-03-28 Alkermes Controlled Therapeutics, Inc. Controlled release growth hormone containing microspheres
EP1649850A1 (en) * 1993-11-19 2006-04-26 Alkermes Controlled Therapeutics Inc. II Preparation of biodegradable microparticles containing a biologically active agent
US5650173A (en) 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
NZ276088A (en) 1993-11-19 1999-07-29 Janssen Pharmaceutica Nv [(1,2-benzisoxazol-3-yl)-1-piperidinyl-alkyl-6,7,8,9-tetrahydro-4h- pyrido[1,2-a]-pyrimidin-4-one derivatives (ie risperidone)
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
GB9718986D0 (en) 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
US6306425B1 (en) * 1999-04-09 2001-10-23 Southern Research Institute Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol
US6331317B1 (en) * 1999-11-12 2001-12-18 Alkermes Controlled Therapeutics Ii Inc. Apparatus and method for preparing microparticles
US6495166B1 (en) * 1999-11-12 2002-12-17 Alkermes Controlled Therapeutics Inc. Apparatus and method for preparing microparticles using in-line solvent extraction
US6264987B1 (en) * 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight

Also Published As

Publication number Publication date
DE60134640D1 (de) 2008-08-14
EP1282404A2 (en) 2003-02-12
EP2258348A3 (en) 2011-10-05
WO2001089482A2 (en) 2001-11-29
ATE399535T1 (de) 2008-07-15
CY1113082T1 (el) 2016-04-13
US6534092B2 (en) 2003-03-18
US20020119203A1 (en) 2002-08-29
AU2001255465B2 (en) 2004-09-23
US20030211164A1 (en) 2003-11-13
EP2258348A2 (en) 2010-12-08
EP1925297B2 (en) 2017-08-16
EP1282404B1 (en) 2008-07-02
US6264987B1 (en) 2001-07-24
US20020001621A1 (en) 2002-01-03
AU5546501A (en) 2001-12-03
DK1925297T3 (da) 2012-10-08
PT1925297E (pt) 2012-10-18
US20030143279A1 (en) 2003-07-31
ES2391315T3 (es) 2012-11-23
CA2405787C (en) 2011-06-14
ES2305071T3 (es) 2008-11-01
EP1925297A1 (en) 2008-05-28
DK1282404T3 (da) 2008-09-01
JP2003534268A (ja) 2003-11-18
PT1282404E (pt) 2008-07-16
CA2405787A1 (en) 2001-11-29
EP1925297B1 (en) 2012-07-11
US6379704B2 (en) 2002-04-30
JP4903344B2 (ja) 2012-03-28
ES2391315T5 (es) 2017-12-20
US20080058502A1 (en) 2008-03-06
WO2001089482A3 (en) 2002-02-21
CY1110403T1 (el) 2015-04-29

Similar Documents

Publication Publication Date Title
DK1925297T4 (da) Fremgangsmåde til fremstilling af mikropartikler med en udvalgt polymermole-kylvægt
ATE267657T1 (de) Verfahren zur herstellung von freiform-produkten
DE60220517D1 (de) Mikroporöse materialien und verfahren zu ihrer herstellung
IL158650A0 (en) Polysiloxane, process for production thereof and radiation-sensitive resin composition
DE60234952D1 (de) VERFAHREN ZUR HERSTELLUNG VON HEXAHYDROFUROc2,3-BÜFURAN-3-OL
DE60110044D1 (de) Teilentwässertes umsetzungsprodukt, verfahren zur herstellung desselben, und dasselbe enthaltende emulsion
PL345215A1 (en) Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same
DK1399133T3 (da) Langvarig frigörelsessammensætning omfattende mælkesyre-glycolsyre copolymer og fremgangsmåde til fremstilling af disse
TW200637885A (en) A composition, method of authenticating, methods of making authenticatable compositions, authenticatable articles made there from
DK1268868T3 (da) Pulvermetallurgisk fremgangsmåde til fremstilling af formede emner med höj massefylde
DK1737807T3 (da) Fremgangsmåde til fremstilling af 1-acetyl-1-chlorcyclopropan
DE60115358D1 (de) Geformter Katalysator zur Herstellung von Triethylendiamin, Verfahren zu dessen Herstellung, und Verfahren zur Herstellung von Triethylendiamin
DE60210778D1 (de) Verfahren zur herstellung von 4-amino-2,5-bisheterocyclylchinazolinen
DE60217249D1 (de) Verfahren zur Herstellung von pressgeformten Gegenständen
DE10085308T1 (de) Polykristallines Material, Verfahren zu dessen Herstellung und daraus hergestellte Gegenstände
DK1165543T3 (da) Fremgangsmåde til fremstilling af [S-(R*,S*)]-G(B)-[[1-[1-oxo-3-(4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-3-pyridinpropansyre og derivater deraf
DK1599433T3 (da) Fremgangsmåde til fremstilling af de enantiomere former af cis-konfigurerede 1,3-cyclohexandiolderivater
DE60113161T2 (de) Verfahren zur herstellung von 2-(4-pyridyl)amino-6-dialkylolxaphenyl-pyrido(2,3-d)pyrimidon-7-on-derivaten
DE60034765D1 (de) Verfahren zur herstellung von poly(p-dioxanon), und poly(p-dioxanon)-monofilament und verfahren zur herstellung desselben
DK1513833T3 (da) Nye forbindelser af 3-(4-oxo-4H-chromen-2-yl)-(1H)-quinolin-4-on, fremgangsmåde til fremstilling af samme samt farmaceutiske sammensætninger indeholdende samme
DE60230097D1 (de) Verfahren zur herstellung von 1,5-diaminonaphthalinen
DE60030428D1 (de) 4-cyano-3-hydroxy-butanoyl hydrazine, derivate und verfahren zu ihrer herstellung
DK1406590T3 (da) Fremgangsmåde til fremstilling af genstande af polymermaterialer med medikamentel depotvirkning
DE60143350D1 (de) Verfahren zur herstellung von 1,3-dialkyl-2-imidazolidinon-derivaten
DK0534347T3 (da) Fremgangsmåde til fremstilling af N-ethylhydroxylamin-hydrochlorid